Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET.
愛爾蘭都柏林，2024年4月1日（GLOBE NEWSWIRE）——專注於改造藥物以改變生活的生物製藥公司Avadel Pharmicals plc（納斯達克股票代碼：AVDL）今天宣佈，管理層成員將參加23日的爐邊談話第三方 年度尼德姆醫療保健會議將於美國東部時間4月8日星期一上午10點15分舉行。
A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following the conference.
會議結束後的90天內，將在Avadel的投資者關係網站investors.avadel.com上直播爐邊談話的網絡直播和存檔錄音。
About Avadel Pharmaceuticals plc
關於 Avadel Pricals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel's commercial product, LUMRYZ, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit .
Avadel Pharmicals plc（納斯達克股票代碼：AVDL）是一家生物製藥公司，專注於改變藥物以改變生活。我們的方法包括將創新的解決方案應用於藥物開發，以應對患者在當前治療選擇中面臨的挑戰。Avadel的商用產品LUMRYZ被美國食品藥品監督管理局（FDA）批准爲首款也是唯一一款用於治療發作性睡病成人過度睡眠或白天過度嗜睡（EDS）的睡前一次的氧合物。欲了解更多信息，請訪問。
Investor Contact:
Courtney Mogerley
Stern Investor Relations, Inc.
Courtney.Mogerley@sternir.com
(212) 698-8687
投資者聯繫人：
考特尼·莫格利
斯特恩投資者關係有限公司
Courtney.Mogerley@sternir.com
(212) 698-8687
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
媒體聯繫人：
萊斯利·斯坦利
真正的化學
lestanley@realchemistry.com
(609) 273-3162
譯文內容由第三人軟體翻譯。